Загрузка...
YL529, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical models
BACKGROUND AND PURPOSE: Targeted chemotherapy using small-molecule inhibitors of angiogenesis and proliferation is a promising strategy for cancer therapy. EXPERIMENTAL APPROACH: YL529 was developed via computer-aided drug design, de novo synthesis and high-throughput screening. The biochemical, pha...
Сохранить в:
| Главные авторы: | , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Blackwell Publishing Ltd
2013
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3753834/ https://ncbi.nlm.nih.gov/pubmed/23594209 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.12216 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|